{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"bioRxiv"}],"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T01:26:52Z","timestamp":1768526812979,"version":"3.49.0"},"posted":{"date-parts":[[2025,11,4]]},"group-title":"Immunology","reference-count":44,"publisher":"openRxiv","license":[{"start":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T00:00:00Z","timestamp":1762214400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2025,11,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                <jats:p>HIV viruses that establish infection possess phenotypic and genotypic characteristics that have been selected for and that differ across transmission routes, including their susceptibility to broadly neutralizing antibodies (bnAbs). While sexually transmitted viruses have been well characterized, studies of vertically transmitted viruses are sparse and from cohorts that are often small in size and more than a decade old. To investigate whether viruses transmitted vertically during lactation possess distinct neutralization profiles compared to viruses transmitted sexually, we compared the neutralization sensitivity of 25 clade C breastmilk viruses to that of 99 contemporaneous clade C viruses from sera of adults with sexual acquisition against three bnAbs in clinical development.Three out of 7 breastmilk donors (43%) had one or more viruses resistant to 2 or more bnAbs, compared to 8 out of 99 (8%) contemporaneous adult viruses (p=0.02). Breastmilk viruses were more resistant to PGT121 and VRC07.523 (median IC80 &gt;50 compared to 1.16 for PGT121, and 12.75 vs. 0.38 for VRC07.523; p=0.013 and &lt;0.001 respectively), and more breastmilk viruses than adult viruses were resistant to VRC07.523 (94% vs. 43%, p=0.001). Interestingly, the breastmilk viruses most resistant to VRC07.523 had on average one or more glycans in V3 compared to adult transmitted viruses (median 3 vs. 2 glycosylation sites, including flanking position 295; p=0.009), and the number of V3 glycans was negatively correlated with VRC07.523 sensitivity (p=0.007). These findings highlight potential differences in bnAb susceptibility of vertically transmitted viruses and emphasize the need to increase sequencing efforts and screening of infant viruses to better inform the efficacy of candidate bnAbs to prevent vertical transmission of HIV.<\/jats:p>","DOI":"10.1101\/2025.11.04.686466","type":"posted-content","created":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T08:40:14Z","timestamp":1762332014000},"source":"Crossref","is-referenced-by-count":0,"title":["Differences in neutralization susceptibility between clade C HIV viruses from breastmilk versus contemporaneous circulating viruses from sexually acquired infections"],"prefix":"10.64898","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2968-1033","authenticated-orcid":false,"given":"Elena E.","family":"Giorgi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin","family":"Gillespie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth","family":"Domin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Genevieve","family":"Fouda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sallie R.","family":"Permar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David C.","family":"Montefiori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Holly","family":"Janes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"54368","reference":[{"key":"2025110701150545000_2025.11.04.686466v1.1","unstructured":"(UNAIDS). JUNPoHA. The Path that Ends AIDS: UNAIDS Global AIDS Update 2023. Geneva, Switzerland: UNAIDS; 2023."},{"key":"2025110701150545000_2025.11.04.686466v1.2","unstructured":"The urgency of now: AIDS at a crossroads \u2013 progress report on the 2025 targets and strategic directions for the future.: Joint United Nations Programme on HIV\/AIDS (UNAIDS); 2025."},{"key":"2025110701150545000_2025.11.04.686466v1.3","doi-asserted-by":"publisher","DOI":"10.1097\/00126334-200402010-00015"},{"key":"2025110701150545000_2025.11.04.686466v1.4","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0802203105"},{"key":"2025110701150545000_2025.11.04.686466v1.5","doi-asserted-by":"publisher","DOI":"10.1089\/AID.2012.0197"},{"key":"2025110701150545000_2025.11.04.686466v1.6","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0009294"},{"key":"2025110701150545000_2025.11.04.686466v1.7","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00197-11"},{"key":"2025110701150545000_2025.11.04.686466v1.8","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1304288110"},{"key":"2025110701150545000_2025.11.04.686466v1.9","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1002686"},{"key":"2025110701150545000_2025.11.04.686466v1.10","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02132-08"},{"key":"2025110701150545000_2025.11.04.686466v1.11","doi-asserted-by":"publisher","DOI":"10.2174\/157016207780076986"},{"key":"2025110701150545000_2025.11.04.686466v1.12","doi-asserted-by":"publisher","DOI":"10.1186\/1742-4690-10-3"},{"key":"2025110701150545000_2025.11.04.686466v1.13","doi-asserted-by":"publisher","DOI":"10.1186\/s12977-017-0331-z"},{"key":"2025110701150545000_2025.11.04.686466v1.14","doi-asserted-by":"crossref","unstructured":"Giorgi EE , Abrahams MR , Fouda G , John-Stewart G , Goga A , Mullins JI , et al. Characterization of Early Viral Populations in Infants Acquiring HIV Through Perinatal and Breastmilk Transmission: A Review of what is Currently Known and the Gaps that Need to be Addressed to Guide Passive HIV Immunization of Breastfeeding Infants. Curr HIV Res. 2025.","DOI":"10.2174\/011570162X357975250902104402"},{"key":"2025110701150545000_2025.11.04.686466v1.15","doi-asserted-by":"crossref","unstructured":"Sutar J , Jayal P , Mullick R , Chaudhary S , Kamble P , Bhowmick S , et al. Distinct region-specific neutralization profiles of contemporary HIV-1 clade C against best-in-class broadly neutralizing antibodies. J Virol. 2025:e0000825.","DOI":"10.1128\/jvi.00008-25"},{"key":"2025110701150545000_2025.11.04.686466v1.16","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1011780"},{"key":"2025110701150545000_2025.11.04.686466v1.17","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1011469"},{"key":"2025110701150545000_2025.11.04.686466v1.18","doi-asserted-by":"crossref","unstructured":"Stefic K , Bouvin-Pley M , Essat A , Visdeloup C , Moreau A , Goujard C , et al. Sensitivity to Broadly Neutralizing Antibodies of Recently Transmitted HIV-1 Clade CRF02_AG Viruses with a Focus on Evolution over Time. J Virol. 2019;93(2).","DOI":"10.1128\/JVI.01492-18"},{"key":"2025110701150545000_2025.11.04.686466v1.19","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1005742"},{"key":"2025110701150545000_2025.11.04.686466v1.20","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02083-14"},{"key":"2025110701150545000_2025.11.04.686466v1.21","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02853-13"},{"key":"2025110701150545000_2025.11.04.686466v1.22","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1003477"},{"key":"2025110701150545000_2025.11.04.686466v1.23","unstructured":"Ballou WR , editor IAVI HIV ebnAb development. HIV Treatment bnAbs: Clinical Research Considerations Workshop; 2023."},{"key":"2025110701150545000_2025.11.04.686466v1.24","unstructured":"Rouzeau R SDAT , Burton I , Shahin L , McKenney K , Chin E , et al., editor In vivo protection by a combination of engineered bNAbs against repeated high-dose mixed-SHIV challenges. 5th HIV Research for Prevention Conference 2004; Lima, peru."},{"key":"2025110701150545000_2025.11.04.686466v1.25","doi-asserted-by":"publisher","DOI":"10.1016\/j.chom.2018.12.001"},{"key":"2025110701150545000_2025.11.04.686466v1.26","doi-asserted-by":"crossref","unstructured":"Roark RS , Li H , Williams WB , Chug H , Mason RD , Gorman J , et al. Recapitulation of HIV-1 Env-antibody coevolution in macaques leading to neutralization breadth. Science. 2021;371(6525).","DOI":"10.1126\/science.abd2638"},{"key":"2025110701150545000_2025.11.04.686466v1.27","doi-asserted-by":"crossref","unstructured":"Mishra N , Sharma S , Dobhal A , Kumar S , Chawla H , Singh R , et al. A Rare Mutation in an Infant-Derived HIV-1 Envelope Glycoprotein Alters Interprotomer Stability and Susceptibility to Broadly Neutralizing Antibodies Targeting the Trimer Apex. J Virol. 2020;94(19).","DOI":"10.1128\/JVI.00814-20"},{"key":"2025110701150545000_2025.11.04.686466v1.28","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M009779200"},{"key":"2025110701150545000_2025.11.04.686466v1.29","doi-asserted-by":"publisher","DOI":"10.1006\/viro.2002.1760"},{"key":"2025110701150545000_2025.11.04.686466v1.30","doi-asserted-by":"publisher","DOI":"10.1172\/JCI81593"},{"key":"2025110701150545000_2025.11.04.686466v1.31","doi-asserted-by":"crossref","unstructured":"Martinez DR , Vandergrift N , Douglas AO , McGuire E , Bainbridge J , Nicely NI , et al. Maternal Binding and Neutralizing IgG Responses Targeting the C-Terminal Region of the V3 Loop Are Predictive of Reduced Peripartum HIV-1 Transmission Risk. J Virol. 2017;91(9).","DOI":"10.1128\/JVI.02422-16"},{"key":"2025110701150545000_2025.11.04.686466v1.32","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1006944"},{"key":"2025110701150545000_2025.11.04.686466v1.33","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e32835faba5"},{"key":"2025110701150545000_2025.11.04.686466v1.34","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.80.2.835-844.2006"},{"key":"2025110701150545000_2025.11.04.686466v1.35","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02316-10"},{"key":"2025110701150545000_2025.11.04.686466v1.36","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.79.16.10108-10125.2005"},{"key":"2025110701150545000_2025.11.04.686466v1.37","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-59745-170-3_26"},{"key":"2025110701150545000_2025.11.04.686466v1.38","doi-asserted-by":"publisher","DOI":"10.1016\/j.jim.2013.11.022"},{"key":"2025110701150545000_2025.11.04.686466v1.39","unstructured":"Dan Barouch BK , Randall Ketchem , Alison Gillespie , Christine Siska , Rutilio Clarrk , Julce Floyd , Jeremy Shaver , Richard Rogers, inventorAntibody therapies for human immunodeficiency virus (HIV) 2019."},{"key":"2025110701150545000_2025.11.04.686466v1.40","doi-asserted-by":"publisher","DOI":"10.1038\/nri2155"},{"issue":"6","key":"2025110701150545000_2025.11.04.686466v1.41","doi-asserted-by":"crossref","first-page":"e405","DOI":"10.1016\/S2352-3018(25)00012-8","article-title":"Safety, pharmacokinetics, and neutralisation activity of PGDM1400LS, a V2 specific HIV-1 broadly neutralising antibody, infused intravenously or subcutaneously in people without HIV-1 in the USA (HVTN 140\/HPTN 101 part A): a first-in-human, phase 1 randomised trial","volume":"12","year":"2025","journal-title":"Lancet HIV"},{"key":"2025110701150545000_2025.11.04.686466v1.42","doi-asserted-by":"publisher","DOI":"10.1038\/nature13612"},{"key":"2025110701150545000_2025.11.04.686466v1.43","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkw256"},{"issue":"52","key":"2025110701150545000_2025.11.04.686466v1.44","first-page":"119","article-title":"Approximate is Better than \u201cExact\u201d for Interval Estimation of Binomial Proportions","volume":"2","year":"1998","journal-title":"The American Statistician"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1101\/2025.11.04.686466","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T09:57:41Z","timestamp":1768471061000},"score":1,"resource":{"primary":{"URL":"http:\/\/biorxiv.org\/lookup\/doi\/10.1101\/2025.11.04.686466"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,4]]},"references-count":44,"URL":"https:\/\/doi.org\/10.1101\/2025.11.04.686466","relation":{},"subject":[],"published":{"date-parts":[[2025,11,4]]},"subtype":"preprint"}}